Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjunct Therapy
9%
Albuminuria
21%
Butyrate
9%
Cardiorenal Protection
9%
Cardiorenal Risk
9%
Cardiovascular Disease
28%
Cardiovascular Risk
20%
Chronic Kidney Disease
6%
Danish Registers
9%
Dapagliflozin
12%
Denmark
6%
Diabetes Management
10%
Diabetic Ketoacidosis
23%
Disease Risk
9%
End-stage Kidney Disease
16%
Endothelial Glycocalyx
9%
Gastrointestinal Diseases
5%
Hemoglobin A1c (HbA1c)
9%
Hospital Admission
9%
Hypoglycemia
5%
Incidence Rate
7%
Inflammation Parameters
9%
Intestinal Inflammation
7%
Ketoacidosis
5%
Kidney Disease
9%
Kidney Parameters
9%
Microvascular Disease
6%
Multifactorial Intervention
9%
Neuropathy
6%
Oxygen Saturation
9%
Perfused Boundary Region
9%
Placebo
7%
Prospective Randomized Trial
9%
Randomized Placebo-controlled Trial
9%
Realist Evaluation
9%
Register Study
9%
Relative Change
7%
Renal Disease
9%
Renal Risk Factors
9%
Risk Engine
27%
Sodium-glucose Cotransporter
27%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
37%
Sodium-glucose Cotransporter Inhibitors
5%
Sotagliflozin
12%
SpO2
9%
Steno
34%
Time Trends
9%
Type 1 Diabetes Mellitus (T1DM)
100%
Type I Diabetes
100%
Vascular Complications
9%
Medicine and Dentistry
Adjuvant Therapy
9%
Albuminuria
19%
Base
9%
Butyric Acid
9%
Cardiovascular Disease
42%
Cardiovascular System
5%
Chronic Kidney Disease
17%
Combination Therapy
5%
Dapagliflozin
12%
Diabetes
33%
Diabetes Mellitus
9%
Diabetic Ketoacidosis
19%
Diabetic Nephropathy
9%
End Stage Renal Disease
13%
Enteritis
5%
Glycocalyx
9%
Hemoglobin A1c
6%
Hypoglycemia
8%
Insulin Dependent Diabetes Mellitus
93%
Ketoacidosis
5%
Maturity Onset Diabetes of the Young
10%
Microvascular Complication
9%
Mineralocorticoid Antagonist
9%
Nephropathy
18%
Neuropathy
6%
Oxygen Saturation
9%
Placebo
14%
Prebiotics
6%
Probiotics
9%
Sodium Glucose Cotransporter 1
9%
Sodium Glucose Cotransporter 2
9%
Sodium Glucose Cotransporter 2 Inhibitor
48%
Sotagliflozin
12%
Supplementation
9%
Synbiotic
9%
Pharmacology, Toxicology and Pharmaceutical Science
Base
9%
Butyrate
9%
Cardiovascular Disease
18%
Cardiovascular Disease
9%
Chronic Kidney Failure
17%
Combination Therapy
5%
Dapagliflozin
13%
Diabetes Mellitus
9%
Diabetic Ketoacidosis
28%
Diabetic Nephropathy
9%
End Stage Renal Disease
7%
Enteritis
5%
Hemoglobin A1c
6%
Inflammation
9%
Insulin Dependent Diabetes Mellitus
65%
Kidney Disease
9%
Mineralocorticoid Antagonist
9%
Non Insulin Dependent Diabetes Mellitus
7%
Placebo
14%
Sodium Glucose Cotransporter 1
9%
Sodium Glucose Cotransporter 2
18%
Sodium Glucose Cotransporter 2 Inhibitor
46%
Sotagliflozin
12%